País: União Europeia
Língua: inglês
Origem: EMA (European Medicines Agency)
Crisaborole
Pfizer Europe MA EEIG
D11AH06
crisaborole
Other dermatological preparations
Dermatitis, Atopic
Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ≤ 40% body surface area (BSA) affected.
Revision: 6
Withdrawn
2020-03-27
24 B. PACKAGE LEAFLET Medicinal product no longer authorised 25 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT STAQUIS 20 MG/G OINTMENT crisaborole This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist, or nurse. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Staquis is and what it is used for 2. What you need to know before you use Staquis 3. How to use Staquis 4. Possible side effects 5. How to store Staquis 6. Contents of the pack and other information 1. WHAT STAQUIS IS AND WHAT IT IS USED FOR Staquis contains the active substance crisaborole. Staquis is used on the skin to control the symptoms of mild to moderate atopic dermatitis in adults and children from 2 years of age. Atopic dermatitis, also called atopic eczema, causes skin inflammation, redness, itchiness, dryness, and thickening in people prone to allergies. The ointment should not be used on more than 40% of your body surface area. Crisaborole, the active substance in Staquis, is thought to work by reducing inflammation and some effects of the immune system (the body’s defences). 2. WHAT YOU NEED TO KNOW BEFORE YOU USE STAQUIS DO NOT USE STAQUIS - if you are allergic to crisaborole or any of the other ingredients of this medicine (listed in section 6). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before using Staquis. Staquis is not for use Leia o documento completo
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Staquis 20 mg/g ointment 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One g of ointment contains 20 mg of crisaborole. Excipients with known effect Propylene glycol, 90 mg/g of ointment For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Ointment. White to off-white ointment. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Staquis is indicated for treatment of mild to moderate atopic dermatitis in adults and paediatric patients from 2 years of age with ≤ 40% body surface area (BSA) affected. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults _ _ _ A layer of ointment is to be applied twice daily to affected areas. The ointment should only be applied to affected skin areas up to a maximum of 40% BSA. The ointment can be used on all skin areas except on the scalp. Use on the scalp has not been studied. The ointment can be used twice daily for up to 4 weeks per treatment course. If any signs and/or symptoms persist, or new areas affected with atopic dermatitis appear, further treatment course(s) can be used as long as the application does not exceed 40% BSA (see section 5.1). Use of the ointment should be discontinued if signs and/or symptoms on treated areas persist after 3 consecutive treatment courses of 4 weeks each or if the signs and/or symptoms worsen during treatment. Medicinal product no longer authorised 3 _Paediatric population _ For children and adolescents (2-17 years) the posology is the same as for adults. The safety and efficacy of Staquis in children less than 2 years of age has not been established. No data are available. _Special populations _ _Hepatic impairment _ Clinical studies in subjects wit Leia o documento completo